QHSLAB INC (USAQ) research, news, and more from GeoInvesting

Company description

Wed, 22 May 2024 13:36:59 GMT

QHSLab, Inc., a medical device technology and software as a service (SaaS) company, focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. The company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. QHSLab, Inc. has a strategic alliance with Medical License Factory, LLC. QHSLab, Inc. was incorporated in 1983 and is based in West Palm Beach, Florida.

Research

Tue, 31 Mar 2026 16:36:27 GMT

Qhslab Inc (OTCQB:USAQ) ($0.57; $8.5M market cap) announced FY 2025 results:

Q4 sales of $703,810 vs $625,981 in the prior year
Q4 2025 EPS: loss of $(0.00) vs $0.00 in the prior year
Fiscal Year sales of $2.7 million vs. $2.1 million in the prior year
Fiscal Year 2025 EPS: loss of $(0.01) vs. loss of $(0.03) in the prior year

Management Commentary:

“Looking ahead to 2026, our focus is on expanding our physician network through targeted hiring of sales personnel, scaling our digital health infrastructure, and continuing to position QHSLab as a trusted partner for primary care practices seeking to implement population-based screening and care management programs. With improving operating fundamentals and a stronger balance sheet, we believe the Company is well positioned to continue building long-term shareholder value.”

Our Quick Take:

USAQ had already pre-announced 2025 results (Jan 26, 2026), so this is not really something new. Also, it’s a little weird that USAQ did not reiterate Q-Cog as a growth engine for 2026, as they did when they published preliminary FY2025 results. However, they did state that they are expanding their physician network through targeted hiring of sales personnel and scaling their digital health infrastructure. Achieving consistent profitability as they scale is what we’re looking for in 2026.

QHSLab, Inc. provides medical device and SaaS-based digital health solutions that support chronic disease management, preventive care, remote patient monitoring, and personalized clinical decision support.

Research

Mon, 26 Jan 2026 19:23:39 GMT

QHSLab, Inc. (OTCQB:USAQ) ($0.92; $12.3M market cap) announced preliminary FY 2025 results:

FY 2025 sales of $2.7 million vs. $2.1 million in the prior year
FY 2025 gross profit: $1.8 million vs. $1.4 million in the prior year
FY 2025 gross margin: 67% vs. 64% in the prior year
Completed major debt restructuring in Q4 2025, reducing convertible debt from $2.0 million to $20,000
Expected annual interest expense to decline by over $200,000
Initial Q-Cog pilot generated early reimbursement activity in December 2025
Management expects Q-Cog to be a meaningful incremental revenue stream in 2026

Management Commentary:

"Our 2025 results reflect the resilience of our business model and the commitment of our team. Even while operating with limited resources and addressing historical obligations, we delivered strong revenue growth, improved profitability, and materially strengthened our financial position for the years ahead,” said Troy Grogan, President and CEO of QHSLab, Inc.

Our Quick Take:

Preliminary results indicate Q4 2025 sales of approximately $688K, representing year-over-year growth of about 10.0%, with growth expected to accelerate as the balance sheet stabilizes and Q-Cog gains momentum from higher reimbursement levels. The reduction in interest expense is especially significant, since it was the primary cause of USAQ’s historical net losses and will enable USAQ to pivot toward profitability. Despite this strong operational momentum, preferred shares could potentially cause significant dilution by increasing the share count by 8 million (USAQ had 13.4M common shares as of January 6, 2026).

Research

Mon, 29 Dec 2025 15:34:36 GMT

QHSLab Inc. (OTCQB:USAQ) ($0.41; $4.6M market cap) announced completion of a $500,000 equity financing and retirement of legacy debt (the legacy notes were retired in November 2025, before this raise)

Amount Raised: $500,000
Type: Private placement of common stock + fixed-price warrants (no convertible notes or debt instruments)
Shares Issued: 1,666,663 common shares at $0.30 per share
Warrants Issued: 416,666 warrants, exercise price $0.60, expiring Dec 31, 2030
Purpose:
- Strengthened balance sheet and liquidity to support working capital and growth initiatives.
- Management intends to expand sales, onboarding, and customer support capacity.

Management Commentary:

"This financing is small in absolute dollars on purpose, but very meaningful at this stage of our evolution. Combined with the recent retirement of our legacy convertible notes, it represents a clear turning point for QHSLab. We have removed a significant source of dilution and interest expense and replaced it with clean equity capital from accredited investors who understand our long-term strategy."

"With nearly $500,000 of new cash on the balance sheet and the elimination of over $1.4 million in defaulted debt, QHSLab enters 2026 with a substantially improved capital structure. This positions us to focus on execution, scaling our digital medicine and integrated service programs, and driving recurring revenue growth without the constant pressure of legacy liabilities."

"As we continue to grow our population and mental health, new cognitive assessments, allergy diagnostics, and preventive care offerings, our priority remains disciplined growth, improving cash flow, and building durable shareholder value. A cleaner balance sheet gives us the foundation to do exactly that."

Our Quick Take:

We added USAQ to our restructuring screen on November 29, 2025, on the heels of its repurchase of legacy debt release. We are scheduling an update call with management. You can get acquainted with the company before the call by viewing these two fireside chats:

Research

Tue, 18 Nov 2025 05:00:00 GMT

QHSLab Inc. (the “Company”) (OTCQB: USAQ), a medical device and digital health company enabling primary care physicians to deliver reimbursable, value-based chronic-disease and preventive-care services, today announced the repurchase and retirement of its outstanding legacy convertible debt issued in 2021 and 2022. The Notes had been in default and carried 18 percent default interest and conversion rights at $0.20 per share. The repurchase will strengthen the Company’s balance sheet, materially reduce future dilution risk, and remove a significant overhang on the Company’s common stock.

Under the terms of the Note Repurchase Agreement, QHSLab successfully retired and cancelled more than $1.4 million of outstanding principal, accrued default interest and potential fees associated with its legacy convertible notes. Upon completion of the transaction, the Notes were extinguished in full, and all related conversion rights, security interests, liens, and claims were permanently terminated.

This action results in a meaningful improvement to QHSLab’s financial position and eliminates several million shares of potential dilution that could have been issued under the Notes’ $0.20 conversion feature.

Financial Highlights – Third Quarter Ended September 30, 2025

Revenue: $737,066, an increase of 35% compared to $544,285 for Q3 2024.
Gross profit: $493,631, up 35% from $365,133 in the prior year quarter, reflecting a gross margin of 67%.
Operating income: $96,251 versus $89,090 in Q3 2024.
Net income: $33,411, compared to net income of $49,765 in Q3 2024.
Cash and cash equivalents: $158,391 at September 30, 2025, steady versus $157,168 at December 31, 2024.

Year-to-Date Highlights (First Nine Months of 2025)

Revenue: $1.99 million, up 32% from $1.51 million for the first nine months of 2024.
Gross profit: $1.32 million (66% gross margin) versus $0.95 million (63% margin) a year ago.
Operating expenses: $1.23 million versus $0.81 million in 2024, driven by continued investment in product development and market expansion.
Net loss: ($99,156) versus net income of $28,350 for the same period last year.
Interest on repurchased convertible notes: Notes eliminate more than $200,000 in annualized interest expense.

Operational and Corporate Updates

Digital Medicine Expansion: QHSLab continued deployment of its ISP platform to primary care and behavioral health practices, increasing recurring SaaS and service revenue.
Product Innovation: Ongoing R&D spending ($132,769 in Q3 2025) supported enhancements to the Q-Cog™ cognitive screening module and Q-Scale™ psychosocial risk tool integrations within electronic health records.
Capital Structure: As of November 20, 2025, the Company had 11,281,527 common shares outstanding.

Management Commentary

Troy Grogan, President and CEO of QHSLab, commented:

“Through the first nine months of 2025, we continued to demonstrate strong operational momentum and revenue growth across our digital health and integrated service program. Our 35 percent year-over-year revenue increase in the third quarter reflects the effectiveness of our technology, the engagement of our physician customers, and the scalability of our solutions within primary care settings.”

“The repurchase of our legacy convertible notes is another important step forward. Eliminating over $1.4 million in defaulted debt obligations significantly strengthens our balance sheet, reduces interest expense going forward, and removes a large conversion overhang that posed a significant dilution risk to our shareholders. This action positions QHSLab for a healthier financial trajectory as we plan our next phase of growth.”

“Looking ahead to 2026, we remain focused on advancing our digital medicine ecosystem, strengthening our relationships with primary-care providers, and expanding collaborative efforts with behavioral health groups. We continue to pursue new opportunities in population health, cognitive assessment, allergy diagnostics, and preventive care. Our priorities include growing recurring revenues, improving cash flow, and leveraging strategic partnerships to support long-term, sustainable profitability. With a cleaner capital structure and stronger financial footing following the retirement of our legacy debt, we believe QHSLab is well-positioned to expand its market presence and deliver lasting value for our shareholders.”

Research

Tue, 18 Feb 2025 12:35:46 GMT

QHSLAB INC (OTCQB:USAQ) – announced it has entered into a strategic partnership with Town Total Compounding, a PCAB-accredited pharmacy specializing in sterile and non-sterile compounding to expand market opportunities.

“This collaboration will introduce QHSLab's Integrated Service Program (ISP) to over 200 primary care medical practices within Town Total’s network, aligning digital medicine assessments with personalized prescription therapies for GLP-1s, Hormone Replacement Therapy (HRT), Allergen Immunotherapy, Pain Management, and Dermatological treatments”.

A Non-Dilutive, Scalable Growth Strategy:

“This co-marketing initiative underscores both companies' commitment to expanding market reach without requiring additional capital investment. By integrating QHSLab’s digital health capabilities into Town Total’s established provider relationships, the partnership fosters organic business growth, enhances provider engagement, and drives better patient adherence and treatment outcomes.”

Research

Mon, 17 Feb 2025 05:00:00 GMT

QHSLAB INC (OTCQB:USAQ) ($0.28; $3.1 M market cap) - announced record revenue growth and positive net income in preliminary Q4 and full year 2024 results:

Revenue surged 98% year-over-year to $625,981, compared to $315,020 in Q4 2023, marking four consecutive quarters of year-over-year revenue growth, marking a milestone year for QHSLab.
Operational efficiencies and strategic execution drive the first profitable year.
Net income for Q4 2024 of $40,838, a significant improvement from a net loss of $86,627 in Q4 2023.
Revenue grew 51% year-over-year, reaching $2.1 million compared to $1.4 million for the full-year 2023.
Gross margin improved to 63.7%, reflecting an enhanced product mix and increased operational efficiencies.
The Company recorded net income of $69,188 for 2024, compared to a net loss of $468,362 in 2023, underscoring QHSLab’s strong financial momentum and commitment to profitable operations.

“These outstanding financial results reflect the continued execution of our strategic initiatives and the growing adoption of our digital medicine solutions,” said Troy Grogan, President and CEO of QHSLab. “We are thrilled to report 98% revenue growth compared to Q4 2023, despite the fourth quarter historically being a lower performing quarter for healthcare companies due to the seasonal impact of patient volume. This growth demonstrates the strength of our business model and the resilience of our operations. Our improved gross margin and profitability highlight the effectiveness of our operational efficiencies and commitment to achieving and sustaining profitability. As we increase the number of physicians using QHSLab, our financial performance should continue to improve.”

Audit status and future outlook:

“The Company is currently finalizing its independent year-end audit in preparation for filing its Annual Report on Form 10-K prior to the 2024 SEC reporting deadline. While these financial results remain unaudited and are subject to change, management is confident in the reported numbers and expects only minor adjustments, if any.

“We look forward to sharing our fully audited results in the coming weeks and remain committed to delivering strong financial performance and value to our shareholders,” added Troy Grogan. “With our continued expansion and operational efficiencies, we are excited about the future of QHSLab as we build on this momentum into 2025.”

In May 2024, Contributor Todd Schuh published an article on USAQ nearing an inflection point, which you can read here.

We continue to monitor to see if the Company will take steps to eliminate convertible debt (when valuing the company investors should note the dilutive effect of the convertible debt of about 10 million shares, which would bring total shares to about 20 million).

QHSLab, Inc. is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians.